rs727502766
Variant summary
Our verdict is Pathogenic. The variant received 15 ACMG points: 15P and 0B. PM1PM2PP2PP3_ModeratePP5_Very_Strong
The NM_005360.5(MAF):c.161C>T(p.Ser54Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_005360.5 missense
Scores
Clinical Significance
Conservation
Publications
- Ayme-Gripp syndromeInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
- cataract 21 multiple typesInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Ambry Genetics
- cataract - microcornea syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- cerulean cataractInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- pulverulent cataractInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Fine-Lubinsky syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 15 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 30
GnomAD4 exome Cov.: 36
GnomAD4 genome Cov.: 30
ClinVar
Submissions by phenotype
Ayme-Gripp syndrome Pathogenic:3
- -
The variant is not observed in the gnomAD v2.1.1 dataset. Predicted Consequence/Location: The variant is located in a mutational hot spot and/or well-established functional domain in which established pathogenic variants have been reported. Missense changes are a common disease-causing mechanism. Functional studies provide moderate evidence of the variant having a damaging effect on the gene or gene product (PMID: 25865493). In silico tool predictions suggest damaging effect of the variant on gene or gene product [REVEL: 0.89 (>=0.6, sensitivity 0.68 and specificity 0.92); 3Cnet: 0.33 (>=0.6, sensitivity 0.72 and precision 0.9)]. Same nucleotide change resulting in same amino acid change has been previously reported to be associated with MAF related disorder (ClinVar ID: VCV000162512 /PMID: 25865493).A different missense change at the same codon (p.Ser54Trp) has been reported to be associated with MAF related disorder (PMID: 30160832). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. -
- -
not provided Pathogenic:1
Published functional studies demonstrate a damaging effect (Niceta et al., 2015); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25865493, 33528093, 31328266, 31600839) -
MAF-related disorder Pathogenic:1
The MAF c.161C>T variant is predicted to result in the amino acid substitution p.Ser54Leu. This variant has been reported to occur de novo in multiple unrelated individuals affected with Ayme-Gripp syndrome (see for example Niceta et al. 2015. PubMed ID: 25865493; Niceta et al. 2019. PubMed ID: 31600839; Chaudhry et al. 2021. PubMed ID: 33528093; Xu et al. 2021. PubMed ID: 34976764). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as pathogenic in ClinVar (ClinVar ID 162512). The c.161C>T (p.Ser54Leu) variant affects one of the four GSK3 phosphorylation motifs and was found to impair MAF phosphorylation and proteasomal degradation in vitro as well as induce neurodevelopmental defects in an in vivo (zebrafish) model (Niceta et al. 2015. PubMed ID: 25865493). Consistent with this, an alternate nucleotide substitution at the same amino acid position designated c.161C>G (p.Ser54Trp) was reported to occur de novo in a patient affected with Ayme-Gripp syndrome (Amudhavalli et al. 2018. PubMed ID: 30160832). Based on the available evidence, this variant is interpreted as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at